Winner of the 2023 PROSE award in Biomedicine and Neuroscience! Research in the field of senescence has boomed recently due to the gradual realization that senescent cells are associated with a significant number of diseases. The genetic or pharmacological elimination of senescent cells can cause widespread benefits and improves outcomes for most of those diseases. Cellular Senescence in Diseases presents an updated review of the role of cellular senescence in multiple pathologies. Focus is given to those diseases where the implication of senescence has been more extensively documented, such as (cancer, lung and liver diseases, diabetes, Neurodegenerative diseases and others). The Editors recruited a group of worldwide experts in each individual pathology to review the role of cellular senescence in each one of them, aiming at identifying potential therapeutic pathways. The first two chapters provide an overview of the cellular senescence principles. Next, the chapters are divided into specific diseases. Cancer, including premalignant lesions (OIS), Advanced disease (TIS), and Metastasis are covered. The following condition covered is Lung diseases, including IPF, COPD, and Pulmonary Hypertension. Next Liver Diseases are covered, including Fibrosis and Cirrhosis, and Fatty liver disease. Next there is coverage for Kidney implications, including fibrosis and transplantation. Vascular diseases are covered next including infarction and hear fibrosis, and atherosclerosis. Both diabetes types 1 and 2 are covered next. Following chapters cover Obesity, Sarcopenia, and Bone and Cartilage disorders, respectively. Neurodegenerative diseases are covered next, focusing on Alzheimer's and Parkinson's. The next chapter discusses accumulation of senescent cell in tissues during aging. The two final chapters cover current developments and conclusions. Cellular Senescence in Diseases is designed for researchers and clinicians with a focus on the cellular mechanisms of diseases. All chapters cover current experimental therapeutic approaches to eliminate or cancel the pathological effects of senescent cells. Pharmaceutical scientists may also benefit from the contents of the book in the exploration of novel therapeutic opportunities.

About the Author
Dr. Manuel Serrano did his PhD under the supervision of Margarita Salas (CBM-CSIC, Madrid) and a postdoctoral stay in David Beach's lab (Cold Spring Harbor Laboratory, NY, USA) from 1992 to 1996. During this time, he made one of his most important contributions, namely the discovery of the tumor suppressor p16. The main contributions of Dr. Serrano's lab during these years are related to the concept of oncogene-induced senescence and the anti-ageing activity of tumor suppressors. More recently, his group has reported on the relevance of tumor suppressors in metabolic syndrome, the existence of senescence during embryonic development, and the feasibility of embryonic reprogramming within living adult organisms (the latter was considered "Achievement of the Year 2013" in the stem cells field by Nature Medicine). Dr. Daniel Munoz-Espin is Senior Research Associate at the Department of Oncology of the University of Cambridge. His lab is part of the CRUK Cambridge Centre Early Detection Programme, working at interface between cellular senescence, plasticity and the fundamental processes and mechanisms that lie at the origin of cancer. We are also developing novel tools and nanodevices for cancer therapy and diagnosis.


Book Information
ISBN 9780128225141
Author Manuel Serrano
Format Paperback
Page Count 472
Imprint Academic Press Inc
Publisher Elsevier Science Publishing Co Inc
Weight(grams) 970g